Overview Research Groups Nuclide Chemistry The focus of our group is the development and application of folic acid based radioconjugates for diagnosis and therapy of folate receptor positive (FR+) cancer and inflammatory diseases which involve activated (FR+) macrophages. Clinical Drug Supply The GMP facilities at the CRS allow the manufacture of safe radiopharmaceuticals for human application. The site is licensed by Swissmedic, the Swiss Agency for Therapeutic Products for the production of radiopharmaceuticals for clinical trials. GMP (Good Manufacture Practice) is a pharmaceutical, legal quality standard for the production of medicinal products. Pharmacology Peptides, such as somatostatin, neurotensin, bombesin bind with high affinity to G-coupled peptide receptors which are often over-expressed on many kind of tumours. Thus, these peptides have a great potential to transport radionuclides into tumours after intravenous application. Radionuclide-Production and Maintenance At present we produce Copper-64, Copper-67 and Zirconium-89 for our current projects. A further area of this group is the design, assembly and installation of chemical equipment in co-operation with the other PSI-staff. Other tasks of the group include maintenance of all our laboratory equipment and the irradiation station. Radionuclide Development The production of dedicated radionuclides and efficient radiochemical isolation of the radioisotopes produced is a joint project of CRS and the laboratory of radiochemistry at PSI. Contact Prof. Dr. Roger Schibli Head of the Center for Radiopharmaceutical Sciences ETH-PSI-USZ roger.schibli@psi.ch +41 56 310 28 37 Sandha Keller Assistentin der Laborleitung sandha.keller@psi.ch +41 56 310 44 05 Contact ETHProf. Dr. Roger SchibliSwiss Federal Institute of Technology ZurichRadiopharmaceutical SciencesETH Zurich
Nuclide Chemistry The focus of our group is the development and application of folic acid based radioconjugates for diagnosis and therapy of folate receptor positive (FR+) cancer and inflammatory diseases which involve activated (FR+) macrophages.
Clinical Drug Supply The GMP facilities at the CRS allow the manufacture of safe radiopharmaceuticals for human application. The site is licensed by Swissmedic, the Swiss Agency for Therapeutic Products for the production of radiopharmaceuticals for clinical trials. GMP (Good Manufacture Practice) is a pharmaceutical, legal quality standard for the production of medicinal products.
Pharmacology Peptides, such as somatostatin, neurotensin, bombesin bind with high affinity to G-coupled peptide receptors which are often over-expressed on many kind of tumours. Thus, these peptides have a great potential to transport radionuclides into tumours after intravenous application.
Radionuclide-Production and Maintenance At present we produce Copper-64, Copper-67 and Zirconium-89 for our current projects. A further area of this group is the design, assembly and installation of chemical equipment in co-operation with the other PSI-staff. Other tasks of the group include maintenance of all our laboratory equipment and the irradiation station.
Radionuclide Development The production of dedicated radionuclides and efficient radiochemical isolation of the radioisotopes produced is a joint project of CRS and the laboratory of radiochemistry at PSI.
Prof. Dr. Roger Schibli Head of the Center for Radiopharmaceutical Sciences ETH-PSI-USZ roger.schibli@psi.ch +41 56 310 28 37
